Wall Street’s Hottest Stock Has a Waiting List. Here’s How to Skip It.

A note from our friends at The Oxford Club(ad)

From the man who tabbed NVIDIA before it soared 6,271%
over 7 years at its peak
Wall Street’s Hottest Stock Has a Waiting List. Here’s How to Skip It.

Wealthy investors are lining up for Anthropic shares and coming up empty. Tech Visionary, Matt McCall, says you can get into a backdoor opportunity today for less than $100 a share.

Anthropic, the company behind Claude, is set to go public at a record $2 trillion valuation.

It could top SpaceX as the biggest IPO in history.

And right now, almost nobody can buy a single share.

One Wall Street broker, whose firm trades about 1,000 private stocks, told TechCrunch:

“The hardest stock to source in our marketplace is Anthropic. There’s just no sellers.”

Even Goldman Sachs is charging clients 15% to 20% of their profits just for a way in.

The Line Is Out the Door

Meanwhile, people who already own a piece of Anthropic are holding on tight.

While everyone else is stuck in line. Even wealthy investors are struggling to get shares.

And it’s all leading to the most anticipated IPO in history.

When Anthropic finally goes public, millions of regular folks will rush to buy whatever they can get.

But tech legend Matt McCall isn’t getting in line.

“Most people are going to wait for Anthropic to go public and then buy as many shares as possible,” he says. “But I think that’s a huge mistake.”

Who Is Matt McCall?

There is a short list of analysts in America who were early on the AI boom.

Matt McCall is one of them.

He’s the Head Innovation Strategist at Monument Traders Alliance and editor of The McCall Innovation Report.

Over the past two decades, McCall has written about 50 stocks that went on to peak gains of 1,000% or more. Including:

  • Tesla, before it climbed as high as 3,129%
  • NVIDIA, before it soared a peak 6,271% in 7 years
  • AMD, which he singled out in 2009

That’s why people call him “Mr. 1,000%.”

On March 6, 2009, McCall went on FOX Business and gave away nine stocks. One was AMD, trading around two dollars. By 2026 it rose 25,000%, enough to turn a $5,000 stake into more than $1.28 million.

No Waiting List Required

McCall’s play isn’t Anthropic. It’s a stock linked to Anthropic that you can buy right now in a regular brokerage account.

No waiting list. No special broker. No fighting Wall Street for scraps.

He calls it a “Second IPO.”

It may sound too good to be true. But it has happened before.

When Rivian went public in 2021, Ford owned a 12% stake. In the six months around Rivian’s IPO, Ford shares roughly doubled.

Yahoo quietly built a huge stake in Alibaba. In the two years around Alibaba’s IPO, Yahoo shares could have tripled your money.

It happened again shortly after EchoStar acquired $8.5 billion in SpaceX shares. In the months leading up to the SpaceX IPO, its shares soared 600%.

Now it’s happening again!

Anthropic’s “Silent Partner”

Years before the IPO frenzy, a much smaller firm took a $100 million stake in Anthropic. It beat Apple, NVIDIA, Amazon and Google to the punch.

Today, the entire company is valued at less than $15 billion. That’s 100x smaller than Anthropic.

McCall believes its early stake could cause it to double or triple in the years ahead.

And you can buy it for less than $100 a share.

We sat McCall down in front of our cameras to get the whole story. He even gave away the name and ticker.

For the time being, you can watch it free.

WATCH THE FREE INTERVIEW (NAME AND TICKER INSIDE)

“If history repeats… investors could double or triple their money in the years ahead.” – Matt McCall

 
 
 
Bonus Article

Imperial Brands Grew EPS 8.8%. Its Buyback Is Growing Too.

When tobacco volumes slide, most analysts stop reading. That is a mistake with Imperial Brands, and this morning’s full-year numbers make the case plainly.

Net revenue growth of 2.1% accelerated to adjusted operating profit growth of 3.7% and further to adjusted EPS growth of 8.8%, supported by cost efficiencies and share buybacks. The EPS number is not a rounding error or a tax windfall. According to the company’s adjusted EPS bridge in its FY26 results slides, improvements in adjusted operating profit contributed 17.8p to adjusted EPS, while the reduction in the share count contributed a further 18.3p, meaning the buyback made a slightly larger contribution to EPS growth than the improvement in operating profit itself.

That arithmetic is the thesis. Imperial is not growing its way to higher earnings; it is engineering higher per-share earnings by retiring stock at a consistent pace. The company increased its full-year dividend to 166.72p per share from 160.32p, and following completion of a £1.45 billion buyback for FY2026, it has commenced a £1.5 billion repurchase programme for FY2027. Against a market capitalisation of roughly £22 billion, that buyback represents close to 7% of the company being returned to shareholders in a single year.

The compounding logic behind aggressive buybacks is not sector-specific. Berkshire’s $9.6 billion repurchase programme illustrates how share count reduction drives per-share value independent of underlying earnings growth.

The headline reported numbers will attract criticism. Reported operating profit fell 10.2% to £3.134 billion because of the Delaware settlement and costs tied to the company’s 2030 strategy. Those are real cash outflows, and investors should not wave them away. But they are also discrete: free cash flow reached £2.6 billion, compared with £2.7 billion in FY25, and Imperial said the period included a c.£150 million cash payment associated with the Delaware settlement. Strip out the settlement and the underlying cash engine barely flinched.

Adjusted operating cash conversion reached 102%, enabling Imperial to maintain leverage at 2.0 times EBITDA, at the lower end of its 2.0 to 2.5 times target range. A company spending aggressively on legal settlements and a restructuring programme while keeping leverage flat is worth a closer look.

The investment case here is not about tobacco recovering. Tobacco net revenue rose 1.7%, as price increases of 5.1% outweighed a 3.4% fall in volumes. The company says this has now held for six consecutive years. What matters for returns is not volume but pricing power plus the buyback, and both are intact.

Pricing power holding through volume declines is not unique to tobacco. Consumer staples brands that kept raising prices without losing buyers show how durable the mechanism can be when category loyalty is high.

For portfolio construction, IMB sits in a category most growth-focused investors have abandoned: a low-beta, high-cash-return consumer defensive with a forward dividend yield above 5% and a free cash flow yield the company itself pegs at around 12%. FY27 guidance is weighted more heavily to the second half because, in the full-year results statement, Imperial flagged supply-chain disruption in Ukraine after an attack on its facilities. That near-term gap is the entry consideration, not the exit.

The risk that matters most is regulatory. Any acceleration in legislation targeting nicotine products across Imperial’s core European markets would pressure volumes faster than pricing can compensate. Free cash flow is expected to reach at least £2.2 billion during FY27, including the impact of 2030 strategy cash expenditure and the second instalment of the Delaware settlement, so the cash distribution floor is lower next year than this. Patient holders accept that.

The broader lesson is mechanical and durable: when a company buys back close to 7% of its shares annually, the per-share economics compound even when the underlying business grows modestly. Imperial Brands is not an exciting business. It is a compounding machine wearing a tobacco label, and that distinction is what the market continues to underprice.